key: cord-1036641-a9b3r6wq
authors: Wali, Arvin R.; Ryba, Bryan E.; Kang, Keiko; Santiago-Dieppa, David R.; Steinberg, Jeffrey; Diaz-Aguilar, Luis Daniel; Stone, Lauren E.; Brandel, Michael G.; Longhurst, Christopher A.; Taylor, William; Khalessi, Alexander A.
title: Impact of COVID-19 on a Neurosurgical Service: Lessons from the University of California, San Diego (USA)
date: 2020-12-30
journal: World Neurosurg
DOI: 10.1016/j.wneu.2020.12.103
sha: 24b938bc402788f7e87b060a6fc0dd9c429e7a5c
doc_id: 1036641
cord_uid: a9b3r6wq

Objective The University of California at San Diego (UCSD) Health system’s institution-wide response to the COVID-19 pandemic was founded on rapid development of in-house testing capacity, optimization of PPE usage, expansion of ICU capacity, development of analytic dashboards for monitoring of institutional status, and implementation of an OR triage plan that postponed non-essential/elective procedures. Here we analyze the impact of this triage plan on the only academic neurosurgery center in San Diego County, California, USA. Methods We conducted a de-identified retrospective review of all operative cases and procedures performed by UCSD Department of Neurosurgery faculty from November 24, 2019, through July 6, 2020, a 226-day period. Statistical analysis involved two-sample z-tests assessing daily case totals over the 113-day periods prior to and after implementation of the OR triage plan on March 16, 2020. Results A total of 1429 surgical and interventional radiologic procedures were performed by the neurosurgical service over the study period. There was no statistically significant difference in the mean number of daily total cases in the pre- versus post-triage plan periods (6.9 versus 5.8 mean daily cases, respectively; 1-tail p = 0.050, 2-tail p = 0.101), a trend reflected by nearly every category of neurosurgical cases. Conclusions We show that during the COVID-19 pandemic, the UCSD Department of Neurosurgery maintained an operative volume that was only modestly diminished and continued to meet the essential neurosurgical needs of a large population. Lessons from our experience can guide other departments as they triage neurosurgical cases to meet community needs.

We reviewed UC San Diego Health's institutional response to the COVID-19 pandemic. 117 The use of widespread in-house testing capacity was crucial to UC San Diego's ability to 118 maximize the safety of both patients and staff. UC San Diego Health became the first health 119 institution in San Diego County, as well as one of the first health institutions nationally, to 120 incrementally implement large-scale in-house COVID-19 PCR and serologic testing. This rapid 121 development of substantial in-house testing was achieved by the UC San Diego Center for 122 Advanced Laboratory Medicine in collaboration with five in vitro diagnostics manufacturers 123 (GenMark Diagnostics, Thermo Fisher Scientific, Roche Diagnostics, Abbott Diagnostics, and 124 Luminex Corporation). As of early April 2020, 700 in-house nucleic acid tests were being 125 performed daily. This capacity has since grown with UC San Diego Health now able to perform 126 in-house up to 1,000 standard COVID-19 PCR tests, 100 "rapid response" COVID-19 PCR tests, 127 and 1,000 serologic tests for COVID-19 antibodies daily. 128 The in-house "rapid response" PCR has seen widespread use both in the emergency 129 department and surgical floor at UC San Diego. These rapid tests can provide results within 1 130 hour of specimen collection and have been implemented as an initial screen for urgent/emergent 131 patients, in order to guide the use of personal protective equipment (PPE) during patient care and patients with a negative "rapid response" PCR receive a follow-up standard COVID-19 PCR in order to ensure adequate screening sensitivity. 3C, respectively). All case data were appropriately de-identified to protect patient privacy, and 206 no protected health information was included. Mean numbers of cases per day by case type were 207 J o u r n a l P r e -p r o o f also computed. The variances in the numbers of cases per day were computed in the pre-and 208 post-triage plan implementation periods, and two-sample z-tests (α = 0.05) were performed. 209 These results are summarized in Table 1 . 30-day rolling averages of daily cases (overall and sub-210 divided by case type) are displayed in Figure 4 . (Table 1) . This represented a mean of 6.3 total cases per day over the entire 246 period. Endovascular procedures, including diagnostic cerebral angiography, accounted for the 247 largest proportion of these cases, at 26.7% of the total ( Figure 3A ) and an overall mean of 1.7 248 cases per day. This was followed by atraumatic operative spinal cases, including spinal tumor 249 (18.8% of the total; mean of 1.2 cases per day; Figure 3A ). Cases involving an endoscopic 250 endonasal approach (EEA) or transsphenoidal approach accounted for the smallest percentage of 251 the total, at 1.6% overall (mean of 0.1 cases per day; Figure 3A ).

A total of 776 surgical and interventional radiologic procedures were performed over the 255 113 days prior to implementation of the UC San Diego COVID-19 OR triage plan on March 16, 256 2020 ( Table 1) . This represented a mean of 6.9 total cases per day over the pre-triage plan 257 period. This decreased slightly to a total of 653 cases over the 113 days after implementation of 258 the OR triage plan and a daily mean of 5.8 total cases per day. The transition to the OR triage 259 plan led to a small relative increase in the proportion of endovascular/diagnostic vascular (26.2% 260 to 27.4%), atraumatic spine (16.2% to 21.7%), trauma/Level 1 (3.2% to 3.7%), and open 261 vascular (1.3% to 2.5%) cases in the post-triage plan period (Figures 3B-C) . This transition also 262 led to a small relative decrease in the proportion of cranial tumor (12.2% to 11.8%), functional 263 and peripheral/cranial nerve (9.0% to 8.6%), shunt (4.5% to 3.8%), EEA/transsphenoidal (1.8% 264 to 1.4%), other IR (19.3% to 14.5%), and miscellaneous (6.2% to 4.6%) cases in the post-triage 265 plan period (Figures 3B-C) . 

The epidemiology and pathogenesis of coronavirus disease 493 (COVID-19) outbreak

Differential Clinical Diagnosis of Novel Coronavirus Disease 2019 (COVID-19)

Disease 2019 (COVID-19): Epidemiology, Pathogenesis, Diagnosis, and 498 Therapeutics

Incidence, clinical outcomes, and transmission 500 dynamics of severe coronavirus disease 2019 in California and Washington: prospective cohort 501 study

Covid-19 in Critically Ill Patients in the 503

Seattle Region -Case Series

Neurological and neuropsychiatric 506 complications of COVID-19 in 153 patients: a UK-wide surveillance study

Neurological associations of COVID-19. The 509 Lancet Neurology

Letter: Adaptation Under Fire: Two Harvard 511

Neurosurgical Services During the COVID-19 Pandemic

Impact of COVID-19 on an Academic 519

Surgery in COVID-19 patients: operational 522 directives

Urologic Surgery and COVID-19: 537 How the Pandemic Is Changing the Way We Operate

COVID-19: impact on 540 colorectal surgery

Epidemiology and Immunization Services Branch. County of San Diego -Coronavirus Disease 543 2019 (COVID-19) Dashboard

California COVID Assessment Tool: Current R-547 effective in California

Rapid response to COVID-19: health 550 informatics support for outbreak management in an academic health system

Palliative Pandemic Plan

Symptoms Algorithm as a Strategy to Decrease Providers' Exposure, While Trying to Increase 554

Teams Availability and Guidance for Goals of Care (GOC) and Symptoms Control